- Exosome isolation by size
- Able to collect intact exosomes
- Ideal for downstream work
- Faster at a lower-cost than ever before
- Medical data and genomic data from
liquid biopsies
- Provides ownership of medical data
to patients
- Started providing solutions for clinical
trial patients
(as a beta-service+POC+revenue model)
- Strong patent strategies
- Korea’s 1st prognosis Dx (IVD III)
- Korea’s 1st companion Dx (IVD III)
- Makes use of liquid biopsy and ddPCR
- IPO to KOSDAQ (2020)
- Chemically defined serum-free media
(CD-M)
- Specific media and manufacturing
solution for hMSC
- Contract development and cell
manufacturing
- Started with cloud base genomic info. mgmt.
- JV between Korea Telecom + Gencurix
- Focuses on NGS-IVD development
- First Korean NGS-CDx development
- CDx based new drug development
- cMET inhibitor (Phase I)
- Proprietary interferon beta products
- Antibody cytokine fusion protein
- Antibody manufacturing tech
- CDx-based drug development
- CTC enumeration & analysis
- Korean FDA Class II cleared solution
- EpCAM, Vimentin and cMET
- Higher purity and recovery rate